Drug Trial Radar · NCT07565155
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jan 1, 2032
Study completion Jan 1, 2032
Sponsor
- Lead sponsor
- University of MiamiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MacroGenics; United States Department of Defense
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to see the effects (good or bad) of Lorigerlimab on patients with pancreatic adenocarcinoma (PDAC) and homologous recombination deficiency (HRD).
Conditions
- Pancreatic Adenocarcinoma
- Homologous Recombination Deficiency
Interventions
LorigerlimabDrug
Participants will be administered 6mg/kg of Lorigerlimab intravenously (IV) on day 1 of every three (3) week cycle (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.